Nordion is a global health science company that provides medical isotopes and sterilization technologies. It has approximately 450 employees serving over 500 customers in more than 40 countries. Nordion is focused on optimizing its medical isotopes business and maintaining its sterilization business. It is also committed to environmental, health and safety standards. Nordion's talented employees work to maintain a global leadership position and build shareholder value.
Companyprofilesandconferences.com glad to promote a new report on "Digna Biotech, S.L. - Product Pipeline Analysis" which are focuses on the development and commercialization of robust clinical therapeutic candidates through partnerships with pharmaceutical companies.
Through practical case studies and industry specific analysis sessions, Medical Device UDIs & Traceability Forum Europe 2015 is geared around strengthening your regulatory infrastructure, maintaining productivity and ensuring ROI from your UDI projects.
View the full agenda here: bit.ly/MedicalDeviceUDI2015Agenda
Alternatively, email enquire@iqpc.co.uk or call +44 (0)207 036 1300 for a copy.
Renal Denervation Systems Market Growth, Demand and Challenges of the Key Ind...IMARC Group
The global renal denervation systems market size reached US$ 218.2 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,723.6 Million by 2027, exhibiting a growth rate (CAGR) of 40.67% during 2022-2027.
More Info:- https://www.imarcgroup.com/renal-denervation-systems-market
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. 2
Caution on Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under
applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that are
not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”
and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements are
necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical trends,
current conditions and expected future developments, as well as other factors that we believe are appropriate in the
circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and
contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-
looking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and
risk factors referred to in our 2012 Annual Information Form (AIF).
We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could
cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not
assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to
time by us or on our behalf, except as required by applicable law.
3. 3
About Nordion
Delivering quality products to our global
customers for more than 60 years, our product
portfolio includes:
• Sterilization Technologies
• Medical Isotopes
Nordion is a health science company that
provides market-leading products used for
the prevention, diagnosis and treatment of
disease.
4. 4
A Global Company
APPROXIMATELY
450 EMPLOYEES
SUPPLY OVER
500 CUSTOMERS
AROUND
30 PRODUCTS
ACROSS MORE THAN
40 COUNTRIES
68%
UNITED STATES
18%
ROW
10%
EUROPE
4%
CANADA
F2012 REVENUES BY REGION - $244.8M*
*Revenues and regional breakdown include Targeted Therapies business, which was divested in July 2013 to BTG plc.
5. 5
103.6 108.7 95.4
89.4
122.8
101.0
29.0
42.6
48.5
0
50
100
150
200
250
300
2010 2011 2012
2012 Financial Highlights
Revenue Trend (US$ Millions)
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
** Key supplier down for repairs for 10 months in F2010
Medical Isotopes** Targeted Therapies*Sterilization Technologies
6. 6
47.5 46.1
39
13.4
38.3
29.4
9.1
12.7
14.1
0
20
40
60
80
100
120
2010 2011 2012
2012 Financial Highlights
Segment Earnings Trend (US$ Millions)
Medical Isotopes** Targeted Therapies*Sterilization Technologies
Excludes corporate segmented loss
* In July 2013, Nordion divested its Targeted Therapies business to BTG plc
** Key supplier down for repairs for 10 months in F2010
7. 7
Q3 2013 Results
32.1
36.5
22.0
24.0
13.0
11.1
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2012 2013
Q3 Q3
Segmented Revenue
(US$ millions)
Segmented Earnings*
(US$ millions)
14.4
17.8
4.6
5.94.3
0.5
0
5
10
15
20
25
30
2012 2013
* Excludes corporate segmented loss
** In July 2013, Nordion divested its Targeted Therapies business to BTG plc
Medical Isotopes Targeted Therapies**Sterilization Technologies
8. 8
F2013 Timeline
DEC 4
Provided
update on
arbitration-
related costs
by AECL
JAN 26
Filed amended
statement of
claim against
AECL
JAN 28
Appointed
Grant Gardiner
as
SVP, General
Counsel
MAY 23
Entered into
agreement to
divest Targeted
Therapies business
to BTG
JUL 15
Announced
divestiture
completion of
Targeted Therapies
business to BTG
MAR 21
Settled claims
with
Dr. Reddy's
Labs
MAY 15
Signed contract
manufacturing
agreement with
Navidea
AUG 20
Reach settlement
with AECL to
resolve MAPLE
lawsuits and
arbitration costs
Update – remove Sept 5
9. 9
Leading Products in Global Markets
POTENTIAL >
< PRIORITY >
STERILIZATION
TECHNOLOGIES
TARGETED
THERAPIES
ADVANTAGE >
Optimize Medical Isotopes
business
• Pursue long-term supply
• Maintain customer
relationships
• Transition business to BTG
plc
• Maintain quality customer
service and supplier
relationships
Maintain Sterilization
business; selectively invest
in growth:
• Geographic expansion
• New applications
• Global leader in cobalt-60
• Significant barriers to entry
• Solid cash flow and gross
margins
• Recurring revenue base
• A global provider in
processing, packaging, &
delivery
• Extensive regulatory
expertise and logistics &
distribution network
Approximately 40% of single-
use medical products
worldwide are sterilized using
gamma sterilization
technologies
Over 10,000 hospitals
worldwide use radioisotopes
in medical procedures with
about 90% being for
diagnosis.
MEDICAL
ISOTOPES
DIVESTED BUSINESS GO-FORWARD BUSINESSES
10. 10
Specialty Isotopes: Sterilization Technologies
• Gamma sterilization is focused on
the prevention of disease
• Co-60 is used to sterilize medical devices,
instruments and supplies and food
• Customers of Co-60 include
contract sterilization service providers
and medical device and product manufacturers
• The Nordion Gamma Centre of Excellence is a
world class applied research and specialty gamma
processing facility to promote and expand the use
of gamma globally
• Nordion manufactures Co-60 irradiation sources,
and designs, constructs and maintains commercial
gamma sterilization systems
11. 11
MARKET MIX PRODUCTS DRIVERS
80%
10%
• Stents
• Patches
• Tissue
• Regen medicine
+ Aging population
+ Enhance devices
+ Leverage drugs
+ Stem cell research
10%
Sterilization Market Segmentation
MEDICAL & SURGICAL
BIO-ACTIVE DEVICES
FOOD SAFETY
• Syringes
• Catheters
• Drapes, gowns
• Sutures, gloves
+ Aging population
+ Min invasive surgery
+ Smaller devices
+ Material
• Fruits & vegetables
• Spices
• Meat and poultry
• Ready To Eat (RTE)
+ FDA labeling
+ USDA FEA
+ Food safety concerns
10%
80%
12. 12
Specialty Isotopes: Medical Isotopes
• Medical isotopes are used to prevent, diagnose
and treat disease
• Main isotope supply sources
are nuclear reactors and cyclotrons
• Primary product is Mo-99, which decays for use in
Technetium-99 (Tc-99m) generators, used in
imaging to diagnose heart disease and cancers
• Other Key Reactor Isotopes:
– Xenon-133 (Xe-133), used in lung scans;
– Iodine-131 (I-131), used to treat hyperthyroidism, thyroid
cancer and non-Hodgkin’s lymphoma;
– Iodine-125 (I-125), used to treat prostate cancer;
• Key Cyclotron Isotopes:
– Iodine-123 (I-123), used to diagnose thyroid disease;
– Strontium-82 (Sr-82), used to manufacture rubidium-82
generators, which are used in imaging to diagnose heart
disease
– Thallium-201 (Tl-201), used to diagnose and assess risk of
coronary artery heart disease;
– Palladium-103 (Pd-103), used to treat prostate cancer;
– Indium-111 (In-111) and Gallium-67 (Ga-67) (both used to
diagnose infection and cancer) at our Vancouver facilities
13. 13
Medical Isotopes (Mo-99) Supply Chain
• Established, reliable facilities providing high-quality isotopes to global customers
• Specialty skills in operations, regulatory affairs and global logistics
Irradiation of
HEU targets to
produce crude
isotopes
NUCLEAR
REACTORS
Purification of
Mo-99 and
distribution to global
radiopharmaceutical
manufacturers
MEDICAL ISOTOPE
PROCESSORS
Tc-99m
Generator
manufacturing
and distribution to
radiopharmacies
RADIOPHARMACEUTICAL
MANUFACTURERS
Unit dose
compounding and
distribution to
hospital/departments
RADIOPHARMACIES
AND HOSPITALS
Critical physiological
diagnosis enabling
informed therapeutic
decisions
PHYSICIANS
AND PATIENTS
14. 14
Nordion Environmental, Health,
and Safety (EH&S) Program
• Creating a workplace that enriches
the health and well-being of Nordion
employees
• Demonstrating Environmental, Health,
and Safety (EH&S) regulatory excellence
• Improving EH&S performance –
continually
• Managing EH&S with excellence
15. 15
Nordion Environmental, Health,
and Safety (EH&S) Program
• Implementing measures in the design and operation of all of
our facilities to keep radiation dose received by workers and
the public ALARA (as low as reasonably achievable)
• Implementing an ISO 14001-based environmental
management (EMS) system at our Ottawa site
• Establishing EH&S objectives and targets annually
to continually improve our performance
• Maintaining - and building on - a comprehensive training
program for employees and contractors
• Engraining EH&S excellence into the Nordion culture
• Investing in a world class approach to EH&S
ISO 14001: 2004 certified
Recipient of the Government of Canada 2007 ENERGY STAR ® Market Transformation Award
Practitioner of LeanSigma, a methodology used to continually improve processes
Recipient of an unprecedented ten-year license renewal from the Canadian Nuclear Safety Commission (CNSC)
16. 16
In the Community
Other Programs:
• Employee Giving Program - Nordion
makes donations to not-for-profit
organizations nominated by employees
• Proud sponsor of the Gala for Research,
an annual black-tie event to support
the Ottawa Hospital Research Institute,
the research arm of The Ottawa Hospital
• Sponsor and key supporter of the
University of Ottawa Heart Institute
Telethon
Ride the Rideau
Title sponsor of Ride the Rideau since its inauguration in 2010, Nordion has helped to
raise over $4.4 million for cancer research at The Ottawa Hospital Research Institute.
17. 17
The talented, dedicated and
resilient people that make
up Nordion share a single
purpose:
• Maintain a global leadership
position in our key markets
• Build value for shareholders
through the execution of our
strategic priorities
• Be a trusted, world-class provider
of healthcare products to our
customers
Business Outlook